Zobrazeno 1 - 10
of 102
pro vyhledávání: '"Adrian Merlo"'
Autor:
Leszek Krolicki, Jolanta Kunikowska, Dominik Cordier, Nedelina Slavova, Henryk Koziara, Frank Bruchertseifer, Helmut R. Maecke, Alfred Morgenstern, Adrian Merlo
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 21, p 15701 (2023)
The median survival time has been reported to vary between 5 and 8 years in low-grade (WHO grade 2) astrocytoma, and between 10 and 15 years for grade 2 oligodendroglioma. Targeted alpha therapy (TAT), using the modified peptide vector [213Bi]Bi/[225
Externí odkaz:
https://doaj.org/article/5f7eace794a54d94b123a21677b6a966
Autor:
Roland M Huber, Michal Rajski, Balasubramanian Sivasankaran, Gerald Moncayo, Brian A Hemmings, Adrian Merlo
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e57793 (2013)
Glioblastoma (GBM) is a highly malignant primary tumor of the central nervous system originating in glial cells. GBM results in more years of life lost than any other cancer type. Low levels of Notch receptor expression correlates with prolonged surv
Externí odkaz:
https://doaj.org/article/b325cbee6cc34797837dff071908db3b
Autor:
Serdar Korur, Roland M Huber, Balasubramanian Sivasankaran, Michael Petrich, Pier Morin, Brian A Hemmings, Adrian Merlo, Maria Maddalena Lino
Publikováno v:
PLoS ONE, Vol 4, Iss 10, p e7443 (2009)
Cancers are driven by a population of cells with the stem cell properties of self-renewal and unlimited growth. As a subpopulation within the tumor mass, these cells are believed to constitute a tumor cell reservoir. Pathways controlling the renewal
Externí odkaz:
https://doaj.org/article/a73b49b97ab54183acd4431e96a2dfa8
Autor:
Jean-Louis Boulay, André R Miserez, Christian Zweifel, Balasubramanian Sivasankaran, Veronika Kana, Anthony Ghaffari, Cordelia Luyken, Michael Sabel, Abdessamad Zerrouqi, Morten Wasner, Erwin Van Meir, Markus Tolnay, Guido Reifenberger, Adrian Merlo
Publikováno v:
PLoS ONE, Vol 2, Iss 6, p e576 (2007)
The structural complexity of chromosome 1p centromeric region has been an obstacle for fine mapping of tumor suppressor genes in this area. Loss of heterozygosity (LOH) on chromosome 1p is associated with the longer survival of oligodendroglioma (OD)
Externí odkaz:
https://doaj.org/article/77770f9921eb480f84b40d912ee08d71
Autor:
Leszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer, Radosław Kuliński, Dariusz Pawlak, Henryk Koziara, Rafał Rola, Alfred Morgenstern, Adrian Merlo
Publikováno v:
Clinical Nuclear Medicine. 48:387-392
Autor:
Silvia Hofer, Luigi Mariani, Karl Frei, Adrian Merlo, Yasuhiro Yonekawa, Frank L. Heppner, Arend Koch, Matthias S. Matter, Marie-France Hamou, Wanyu L. Lambiv, Mauro Delorenzi, Mathilde C. M. Kouwenhoven, Yuta Kamoshima, Pierre Bady, Annie-Claire Diserens, Monika E. Hegi
Supplementary Methods, Figure Legends 1-5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e98b95440308927845df74b2956ae87
https://doi.org/10.1158/1535-7163.22496533.v1
https://doi.org/10.1158/1535-7163.22496533.v1
Autor:
Silvia Hofer, Luigi Mariani, Karl Frei, Adrian Merlo, Yasuhiro Yonekawa, Frank L. Heppner, Arend Koch, Matthias S. Matter, Marie-France Hamou, Wanyu L. Lambiv, Mauro Delorenzi, Mathilde C. M. Kouwenhoven, Yuta Kamoshima, Pierre Bady, Annie-Claire Diserens, Monika E. Hegi
Supplementary Figure 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a167f30be0851324e54af2254f32854
https://doi.org/10.1158/1535-7163.22496548
https://doi.org/10.1158/1535-7163.22496548
Autor:
Silvia Hofer, Luigi Mariani, Karl Frei, Adrian Merlo, Yasuhiro Yonekawa, Frank L. Heppner, Arend Koch, Matthias S. Matter, Marie-France Hamou, Wanyu L. Lambiv, Mauro Delorenzi, Mathilde C. M. Kouwenhoven, Yuta Kamoshima, Pierre Bady, Annie-Claire Diserens, Monika E. Hegi
Supplementary Table 1 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fc6ef17600cd0c658f260ffb1ef3544
https://doi.org/10.1158/1535-7163.22496530
https://doi.org/10.1158/1535-7163.22496530
Autor:
Silvia Hofer, Luigi Mariani, Karl Frei, Adrian Merlo, Yasuhiro Yonekawa, Frank L. Heppner, Arend Koch, Matthias S. Matter, Marie-France Hamou, Wanyu L. Lambiv, Mauro Delorenzi, Mathilde C. M. Kouwenhoven, Yuta Kamoshima, Pierre Bady, Annie-Claire Diserens, Monika E. Hegi
Supplementary Figure 5 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63354b5b7f95265360173c47fe71006d
https://doi.org/10.1158/1535-7163.22496536.v1
https://doi.org/10.1158/1535-7163.22496536.v1
Autor:
Silvia Hofer, Luigi Mariani, Karl Frei, Adrian Merlo, Yasuhiro Yonekawa, Frank L. Heppner, Arend Koch, Matthias S. Matter, Marie-France Hamou, Wanyu L. Lambiv, Mauro Delorenzi, Mathilde C. M. Kouwenhoven, Yuta Kamoshima, Pierre Bady, Annie-Claire Diserens, Monika E. Hegi
Supplementary Table 2 from Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8584e250758df6769b27bf0e2a92cfda
https://doi.org/10.1158/1535-7163.22496527.v1
https://doi.org/10.1158/1535-7163.22496527.v1